T1	intervention 26 56	axillary reverse mapping (ARM)
T3	No-of-participants 1081 1084	280
T5	control 1245 1258	standard ALND
T6	outcome-Measure 1385 1461	axillary surgery-related lymphedema at 6, 12, and 24 months post-operatively
T7	outcome-Measure 1541 1545	pain
T8	outcome-Measure 1547 1558	paresthesia
T9	outcome-Measure 1560 1599	numbness, and loss of shoulder mobility
T10	outcome-Measure 1601 1616	quality of life
T11	outcome-Measure 1622 1646	axillary recurrence risk
T12	location 2026 2037	Netherlands
T2	eligibility 1085 1204	patients diagnosed with SLN biopsy-proven metastasis of invasive breast cancer with an indication for a completion ALND
